BNET Industries

Market Cap:$2.3B
Last Fiscal Year Sales:$333.6M
  • Public
  • US
Dow Jones Description

We are a leading healthcare company focused on the development and marketing of novel molecular diagnostic and therapeutic products. We employ a number of proprietary technologies that permit us to understand the genetic basis of human disease and the role that genes and their related proteins play in the onset, progression and treatment of disease. We use this information to guide the development of new healthcare products that are designed to treat disease and assess a persons risk of disease later in life. Our molecular diagnostic business focuses on the analysis of genes and their alterations to assess an individuals risk for developing disease later in life (predictive medicine) and to assess a patients risk of disease progression, disease recurrence, drug toxicity, and drug response (personalized medicine). To date we have launched five commercial molecular diagnostic products, including both predictive medicine and personalized medicine products. We market these products through our own 200-person sales force in the United States and we have entered into marketing collaborations with other organizations in selected foreign countries. Molecular diagnostic revenue was $222.9 million for the year ended June 30, 2008, an increase of 53% over the prior fiscal year. We believe that the future of medicine lies in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and that may be useful in disease prevention. ...

President & Chief Executive Officer
Peter D. Meldrum
Number of Employees 994
Contact Information

320 Wakara Way

Salt Lake City, Utah 84108

myriad.com

801-584-3600

NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413

Recent Events

  • Morgan Joseph Upgrades Myriad Genetics MYGN to Hold; Expect Positive Sales

    11/11/09 - Bond / Stock Rating - View Story

  • Zacks Bull and Bear of the Day Highlights: Infosys, Myriad Genetics Inc., American International Group,...

    11/16/09 - Financial Announcement - View Story

  • Court Refuses to Dismiss Gene Patent Challenge

    11/03/09 - Lawsuit Filed - View Story

  • Hereditary Breast and Ovarian Cancer

    10/13/09 - Product Announcement - View Story

  • Myriad Genetics to Report Fiscal 2010 First Quarter Financial Results On November...

    10/13/09 - Financial Announcement - View Story

  • BRIEF-Myriad Genetics elects Louise Phanstiel and Lawrence Best to board

    9/21/09 - Board Member - Entering - View Story

  • Myriad posts higher revenue, earnings: SLC firm optimistic about diagnostic products.

    8/26/09 - Financial Announcement - View Story

  • Notable Analyst Rating Changes 8/4: HBC, HGSI, PKY, DISH, TLB Upgraded; HOLX, ATML, ABX, STEC,...

    8/04/09 - Bond / Stock Rating - View Story

  • Morgan Joseph Downgrades Myriad Genetics MYGN from Buy to Sell; Lowers Estimates

    7/01/09 - Bond / Stock Rating - View Story

  • Myriad Problems for Myriad Genetics

    7/01/09 - Financial Announcement - View Story

News & Analysis

myriad genetics inc. and trader mark - All News and Analysis

  • Myriad's Monster Results

    Seeking Alpha - 2009-02-04

    Trader Mark submits: Myriad Genetics MYGN has been a name I had been hoping to buy on a pullback closer to mid $60s [Jan 20: Myriad Genetics - Another Diagnostic Heavy Hitter] - but it refused to fall during this multi-week correction in the general market. Now we see...

    Tags: Biotech, Trader Mark, Myriad Genetics Inc.

  • Myriad Genetics - A Diagnostics Heavy Hitter

    Seeking Alpha - 2009-01-21

    Trader Mark submits: Along with Sequenom SQNM, another name I've been watching for quite a while in the healthcare diagnostic area is Myriad Genetics MYGN. Both were mentioned in a blog entry from August 2008 [Aug 25: Sequenom Flying off a Positive Investor's Business Daily Mention]. Their niche is...

    Tags: Biotech, Trader Mark, Myriad Genetics Inc.

Decision Makers

Name (plus bio) Position
Peter D. Meldrum President & Chief Executive Officer
Gregory C Critchfield President, Myriad Genetic Laboratories, Inc.
James S. Evans Chief Financial Officer
Mark C. Capone Chief Operating Officer
Mark H. Skolnick Chief Scientific Officer
Robert G Harrison Chief Information Officer
Jerry Lanchbury Executive Vice President, Research & Development
Richard Marsh Executive Vice President, General Counsel and Secretary

Board of Directors

Name (plus bio) Position
Dennis H. Langer Board of Directors
Dennis Langer Board of Directors
Gerald P. Belle Board of Directors
Linda S. Wilson Board of Directors
Robert S. Attiyeh Board of Directors
Walter Gilbert Vice Chairman

Organization Position Status
Prolexys Pharmaceuticals, Inc President and Chief Executive Officer Current
Myriad Genetics, Inc. President & Chief Executive Officer Current
Golden Pine Ventures, LLC Chairman, Board of Directors Current
Myriad Genetics, Inc. Board of Directors Current
University of Utah College Board of Directors Current
The Founders Fund Chief Executive Officer Former
Fund Inc Chief Executive Officer Former
The Founders Fund President Former
Fund Inc President Former
University of Utah M.B.A. Degree Former
University of Utah B.S. Degree In Chemical Engineering Former

Gregory Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., a wholly owned subsidiary, joined the Company in July 1998. Dr. Critchfield previously served as Senior Vice President, Chief Medical and Scientific Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Dr. Critchfield received his M.D. from the University of Utah and his M.S. in Biophysical Sciences from the University of Minnesota. He is Board Certified in Clinical Pathology.

Organization Position Status
Myriad Genetics, Inc. President, Myriad Genetic Laboratories, Inc. Current
Biotrove, Inc. Board of Directors Current
Quest Diagnostics Incorporated Senior Vice President, Chief Medical Former
Intermountain Health Care Inc. Director of Clinical Pathology Former
Quest Diagnostics Incorporated Science Officer Former
University of Utah M.D. Former
University of Minnesota M.S. in Biophysical Sciences Former

James S. Evans, Chief Financial Officer, joined Myriad in 1995. Mr. Evans served as Myriad's Corporate Controller from 1995 until July 2005 when he was named Vice President, Finance, a position he held until November 2007 when he was named Chief Financial Officer. Mr. Evans began his career in the Audit/Attestation division of the international accounting firm of KPMG, LLP where he held several positions. He worked as the Controller for Genmark, Inc. and Shaperite Concepts, Ltd. prior to joining Myriad. Mr. Evans received a Bachelor of Science and Master of Accounting degrees from Brigham Young University in 1987 and is a Certified Public Accountant licensed in the State of Utah.

Organization Position Status
Myriad Genetics, Inc. Chief Financial Officer Current
Myriad Genetics, Inc. Vice President, Finance Former
Genmark Controller Former
Myriad Genetics, Inc. Corporate Controller Former

Mark C. Capone, Chief Operating Officer of Myriad Genetics Laboratories, joined the company in October 2002. He was previously Senior Vice President of Sales. Prior to joining Myriad, Mr. Capone served 17 years with Eli Lilly and Company where he held positions as Product Development Manager, Manufacturing Plant Manager, and Area Sales Director. Mr. Capone received his Bachelor of Science degree in Chemical Engineering from Penn State University graduating with highest distinction, his Master of Science degree in Chemical Engineering from Massachusetts Institute of Technology, and his Master of Science in Management from Massachusetts Institute of Technology.

Organization Position Status
Myriad Genetics, Inc. Chief Operating Officer Current
Myriad Genetics, Inc. Sales Executive Former
The Pennsylvania State University B.S. Degree In Chemical Engineering Former

Organization Position Status
Myriad Genetics, Inc. Chief Scientific Officer Current
Trillium Digital Systems, Inc. Current
Myriad Genetics, Inc. Board of Directors Current
Stanford University Ph.D. In Genetics Former
University of California, Berkeley B.A. Degree In Economics Former

Robert G. Harrison, Chief Information Officer, joined Myriad in 1996. Mr. Harrison served as Myriad's Network Administrator from 1996 to 2000. He was then named Director of Information Systems and Technology from 2000 until January 2005. He was then named Vice President of Information Systems and Technology, a position he held until January 2008 when he was named Chief Information Officer. Mr. Harrison began his career in IT working for several private companies and consulting firms where he held several positions in technical support, sales and management capacities. Mr. Harrison received a Bachelor of Science degree in Business Administration with a minor in Computer Science from the University of Utah in 1994.

Organization Position Status
Myriad Genetics, Inc. Chief Information Officer Current
Myriad Genetics, Inc. Data Processing Executive Former
University of Utah Bachelor of Science Degree In Business Administration Former

Jerry Lanchbury, Ph.D., Executive Vice President of Research and Development joined Myriad in September 2002. Dr. Lanchbury graduated from the University of Aston, Birmingham, UK. He earned his doctorate in population genetics from the University of Newcastle upon Tyne and subsequently completed his postdoctoral fellowship at the United Medical & Dental Schools of the University of London in Human Disease Genetics. Dr. Lanchbury is a highly respected expert in immunogenetics with more than 100 reviewed research journal publications.

Organization Position Status
Myriad Genetics, Inc. Executive Vice President, Research & Development Current
University of Newcastle upon Tyne Doctorate In Population Genetics Former
University of Aston Former

Richard Marsh, Executive Vice President, General Counsel and Secretary joined Myriad in November 2002. Prior to joining Myriad, Mr. Marsh served in various positions at Iomega Corporation including Acting General Counsel, Director of IP and Director of Commercial Legal Affairs. Richard received a Masters of Laws degree in Taxation from Georgetown University Law Center; a law degree from Thomas M. Cooley Law School, graduating magna cum laude; and a Bachelor of Science degree in Accounting from Brigham Young University; and was formerly a Certified Public Accountant.

Organization Position Status
Myriad Genetics, Inc. Executive Vice President, General Counsel and Secretary Current
Iomega Corporation Director of Commercial Legal Affairs Former
Iomega Corporation Acting General Counsel Former
Iomega Corporation Secretary Former
Cooley Law School Law Degree Former
Georgetown University Law Center Masters of Laws Degree In Taxation Former
Brigham Young University undergraduate degree in Accounting Former
Brigham Young University undergraduate degree in Accounting Former

Organization Position Status
Cytogen Corporation Managing Partner of Phoenix Ip Ventures Current
Georgetown University School of Medicine Clinical Professor Current
Department of Psychiatry Clinical Professor Current
03.Tilt Chairman Current
Inotek Pharmaceuticals Corporation Board of Directors Current
Myriad Genetics, Inc. Board of Directors Current
Sirna Therapeutics, Inc. Board of Directors Current
Cytogen Corporation Board of Directors Current
Pharmacopeia Drug Discovery Inc. Board of Directors Current
Auxilium Pharmaceuticals, Inc. Board of Directors Current
Visitors Board of Directors Current
Ception Therapeutics, Inc. Director Current
Neose Technologies, Inc. Chief Executive Officer Former
Dr. Reddy's Laboratories Limited President Former
Neose Technologies, Inc. first President Former
Yale University School of Medicine Chief Former
GlaxoSmithKline Plc Senior Vice President, Project Former
SmithKline Beecham Corporation Senior Vice President, Research and Development Former
SmithKline Beecham Corporation Vice President Former
Abbott Laboratories Associate Director Former
Abbott Laboratories Senior Product Manager Former
Indiana University School of Medicine Associate Prof Former
National Institutes of Health Clinical Associate Former
Chicago Medical School Associate Prof Former
Informedix, Inc. Chairman Former
SmithKline Beecham Corporation Director Former
Georgetown University School of Medicine M.D. Former
Harvard Law School J.D. (cum laude) Former
Columbia University J.D. Degree Former
Columbia University B.A. in Biology Former
Eli Lilly and Company Associate Clinical Investigator Former

Organization Position Status
Cytogen Corporation Managing Partner of Phoenix Ip Ventures Current
Georgetown University School of Medicine Clinical Professor Current
Department of Psychiatry Clinical Professor Current
03.Tilt Chairman Current
Myriad Genetics, Inc. Board of Directors Current
Ception Therapeutics, Inc. Director Current
Sirna Therapeutics, Inc. Board of Directors Current
Inotek Pharmaceuticals Corporation Board of Directors Current
Cytogen Corporation Director Current
Visitors Board of Directors Current
Neose Technologies, Inc. Chief Executive Officer Former
Dr. Reddy's Laboratories Limited President Former
Neose Technologies, Inc. President Former
Yale University School of Medicine Chief Former
SmithKline Beecham Corporation Senior Vice President, Product Development Strategy Former
GlaxoSmithKline Plc Senior Vice President, Project Former
SmithKline Beecham Corporation Vice President Former
Abbott Laboratories Associate Director Former
Abbott Laboratories Senior Product Manager Former
National Institutes of Health Clinical Associate Former
Indiana University School of Medicine Associate Prof Former
Chicago Medical School Associate Prof Former
Informedix, Inc. Chairman Former
SmithKline Beecham Corporation Director Former
Harvard Law School J.D. (cum laude) Former
Georgetown University School of Medicine M.D. Former
Columbia University J.D. Degree Former
Eli Lilly and Company Associate Clinical Investigator Former
Columbia University B.A. Degree In Biology Former

Organization Position Status
Merial Ltd Chairman Current
Myriad Genetics, Inc. Board of Directors Current
PDI, Inc. Board of Directors Current
Aventis Pharmaceuticals Inc President and CEO, North American Pharmaceuticals Former

Linda Wilson, Lead Teacher, Fifth Grade, is in her ninth year of teaching and her second at CLCS. She has degrees from the University of Wisconsin and Cardinal Stritch College. Before coming to CLCS, Ms. Wilson integrated music with instruction and is happy to now be teaching at a school with a Learning through Music model. Ms. Wilson plays clarinet and is learning to play violin.

Organization Position Status
Conservatory Lab Charter School Lead Teacher, Fifth Grade Current
Tulane University Board of Directors Current
Myriad Genetics, Inc. Board of Directors Current
Radcliffe College President Former
University of Michigan Vice President of Research Former
University of Illinois Vice President of Research Former
Research, Inc. Associate Former
Massachusetts Gen Hospital Board of Directors Former
Massachusetts General Hospital Board of Directors Former
Visitors Board of Directors Former
University of Wisconsin Doctoral Degree In Chemistry Former
Newcomb College, Inc. B.A. In Chemistry Former

Robert S. Attiyeh, Member of the Board of Directors, was elected to the board in 2003. He currently serves as Chairman of the Board's audit committee. Mr. Attiyeh is a principal in the real estate investment firms of Beacon Hill Properties LLC and Yarlung LLC. He previously served Amgen from 1994 - 1998 as Senior Vice President, Finance and Corporate Development and as Chief Financial Officer. Prior to joining Amgen, Mr. Attiyeh was a director of McKinsey and Company from 1967 - 1994. He was a Director of the Federal Reserve Bank of San Francisco from 1987 - 1992 and served as Chairman of the Audit Review Committee of the Bank's Board from 1988 - 1992. He is currently on the Board of Directors of Source Precision Medicine of Boulder, Colorado, where he is Chairman of the Board's Audit Committee. Mr. Attiyeh holds a masters in business administration from Harvard and an electrical engineering degree from Cornell. Mr. Attiyeh is a member of Class Three of the Board, with a term expiring at our 2009 annual meeting.

Organization Position Status
International Rectifier Corporation Board of Directors Current
Myriad Genetics, Inc. Board of Directors Current
Bloggingbuyouts Director Current
Amgen Inc. Chief Financial Officer Former
Amgen Inc. Senior Vice President, Finance and Corporate Development Former
Beacon Hill Properties, LLC Manager Former
Beacon Hill Properties, LLC Principal In the Real Estate Former
Federal Reserve Bank of San Francisco Audit Review Committee Chairman Former
Federal Reserve Bank of San Francisco Director Former
McKinsey & Company, Inc. Director Former
Cornell University Masters In Business Former
Harvard University MBA Former
Harvard Corporation Masters In Business Administration Former
Cornell University bachelor's degree in electrical engineering Former
Cornell University Degree Former

Organization Position Status
Cylene Pharmaceuticals, Inc. Nobel Laureate and Managing Director, Bioventures Investors Current
Paratek Pharmaceuticals, Inc. Co-Founder Current
Cytonome, Inc. Founder Current
Memory Pharmaceuticals Corp. Director Current
Paratek Pharmaceuticals, Inc. Chairman of the Board of Directors Current
Biotechnology Council of New Jersey, Inc Member of the Board of Directors Current
Alta Partners Director Current
Activbiotics Inc. Board of Directors Current
Cylene Pharmaceuticals, Inc. Board of Directors Current
Myriad Genetics, Inc. Vice Chairman Current
The Royal Society Board of Directors Current
National Academy of Sciences Board of Directors Current
Cytonome, Inc. Board of Directors Current
Bioventures Investors CEO Former
Biogen, Inc. CEO Former
Memory Pharmaceuticals Corp. Chief Executive Officer Former
Biogen Idec, Inc. CEO Former
Biogen Idec, Inc. founder Former
Biogen, Inc. Founder Former
Memory Pharmaceuticals Corp. Co-Founder Former
Myriad Genetics, Inc. Co-Founder Former
Cylene Pharmaceuticals, Inc. Founder Former
Cylene Pharmaceuticals, Inc. General Partner, Bioventures Former
Cylene Pharmaceuticals, Inc. Senior Executive Former
Harvard University Professor Former
Pfizer Inc. Former
Bioventures Investors General Partner Current
Memory Pharmaceuticals Corp. Chairman of the Board of Directors Former
University of Cambridge Ph.D. Degree In Mathematics Former
Cambridge University Ph.D. in Mathematics Former
Harvard University M.A. In Physics Former
University of London Master S of Science In Pharmacology and Is A Member of the Chartered Institute of Marketing. Former
Harvard College A.B. in Chemistry and Physics (summa cum laude) Former
University of Cambridge B.S. Degree In Chemistry Former
Memory Pharmaceuticals Corp. Member Former
National Academy of Sciences Member Former
advertisement
     MYGN $23.95 -0.16 (-0.66% )
Average Volume 1,525,650
Shares Outstanding 96.20M
Market Cap 2.3B
Year High 89.84
Year Low 22.38
Earnings Per Share 1.54
P/E Ratio 15.55
Dividend N/A
Yield N/A
advertisement